{"id":17458,"date":"2025-01-29T20:46:00","date_gmt":"2025-01-29T13:46:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=17458"},"modified":"2025-01-29T20:46:00","modified_gmt":"2025-01-29T13:46:00","slug":"asia-book-of-records-honors-cipla-emerging-markets-europe-business-unit-for-record-breaking-doctor-engagement-on-copd-awareness-initiative","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=17458","title":{"rendered":"Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cipla’s (EMEU BU) ‘Take Charge \u2013 I Pledge’ campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness. <\/i><\/p>\n

MUMBAI, India<\/span><\/span>, Jan. 29, 2025<\/span><\/span> \/PRNewswire\/ — Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as “Cipla” today announced that its Emerging Markets & Europe Business Unit (EMEU BU) <\/b>has achieved a new milestone by being recognized in the Asia Book of Records. During COPD Awareness Month, Cipla successfully engaged 4,350 doctors from Nepal<\/span>, Myanmar<\/span>, Sri Lanka<\/span>, Malaysia<\/span>, Oman<\/span>, and the UAE<\/b> in a pledge campaign to raise awareness about Chronic Obstructive Pulmonary Disease (COPD). The initiative, titled ‘Take Charge \u2013 I Pledge,’ aimed to foster meaningful dialogue between healthcare professionals, patients, and caregivers, reinforcing Cipla’s commitment to respiratory disease awareness.<\/p>\n

This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month.<\/p>\n

Commenting on this recognition, Swapn Malpani, CEO \u2013 Cipla EMEU<\/b> said, “COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of death worldwide. In 2021, it accounted for about 3.5 million deaths, which is roughly 5% of all deaths globally. By encouraging doctors to participate in the ‘Take Charge \u2013 I Pledge’ campaign, our aim was to highlight the significance of timely diagnosis and effective management in enhancing long-term health outcomes. The campaign aimed to strengthen the doctor-patient relationship by promoting open dialogue, which can result in better understanding and improved care for those living with COPD.”<\/p>\n

About Cipla<\/b><\/p>\n

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India<\/span>, South Africa<\/span>, North America<\/span>, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd<\/i> largest in pharma in India<\/span> (IQVIA MAT Dec’24), Largest in the pharma prescription market in South Africa<\/span> (IQVIA MAT Nov’24), and 4th<\/i> largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Nov’24). For more, please visit www.cipla.com<\/a>, or click on Twitter<\/a>,\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>.<\/p>\n

Media Contact:<\/b>
Investor Relations \u00a0\u00a0
E-mail: Investor.Relations@cipla.com<\/a>\u00a0 \u00a0 \u00a0\u00a0<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Cipla’s (EMEU BU) ‘Take Charge \u2013 I Pledge’ campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness. <\/i><\/p>\n

MUMBAI, India<\/span><\/span>, Jan. 29, 2025<\/span><\/span> \/PRNewswire\/ — Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as “Cipla” today announced that its Emerging Markets & Europe Business Unit (EMEU BU) <\/b>has achieved a new milestone by being recognized in the Asia Book of Records. During COPD Awareness Month, Cipla successfully engaged 4,350 doctors from Nepal<\/span>, Myanmar<\/span>, Sri Lanka<\/span>, Malaysia<\/span>, Oman<\/span>, and the UAE<\/b> in a pledge campaign to raise awareness about Chronic Obstructive Pulmonary Disease (COPD). The initiative, titled ‘Take Charge \u2013 I Pledge,’ aimed to foster meaningful dialogue between healthcare professionals, patients, and caregivers, reinforcing Cipla’s commitment to respiratory disease awareness.<\/p>\n

This achievement has been recognised by the Asia Book of Records for engaging the largest number of doctors in a COPD awareness campaign during COPD Awareness Month.<\/p>\n

Commenting on this recognition, Swapn Malpani, CEO \u2013 Cipla EMEU<\/b> said, “COPD is recognized as a progressive lung condition and ranks as the fourth leading cause of death worldwide. In 2021, it accounted for about 3.5 million deaths, which is roughly 5% of all deaths globally. By encouraging doctors to participate in the ‘Take Charge \u2013 I Pledge’ campaign, our aim was to highlight the significance of timely diagnosis and effective management in enhancing long-term health outcomes. The campaign aimed to strengthen the doctor-patient relationship by promoting open dialogue, which can result in better understanding and improved care for those living with COPD.”<\/p>\n

About Cipla<\/b><\/p>\n

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India<\/span>, South Africa<\/span>, North America<\/span>, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd<\/i> largest in pharma in India<\/span> (IQVIA MAT Dec’24), Largest in the pharma prescription market in South Africa<\/span> (IQVIA MAT Nov’24), and 4th<\/i> largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Nov’24). For more, please visit www.cipla.com<\/a>, or click on Twitter<\/a>,\u00a0Facebook<\/a>,\u00a0LinkedIn<\/a>.<\/p>\n

Media Contact:<\/b>
Investor Relations \u00a0\u00a0
E-mail: Investor.Relations@cipla.com<\/a>\u00a0 \u00a0 \u00a0\u00a0<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-17458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17458"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17458\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}